MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma

Trial Profile

MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects with Severe Refractory Asthma

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Asthma
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms SIRIUS
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 May 2017 Results of a post-hoc analysis presented at the 113th International Conference of the American Thoracic Society.
    • 06 Mar 2017 Results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 18 Apr 2016 Results of pooled post-hoc analysis of two phase III studies (MENSA and SIRIUS) published in the Allergy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top